Benno Rattel

Amgen (Germany) — Germany

Medicine · Health Sciences

18h-index1.7kcitations69works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(36), CAR-T cell therapy research(24), Prostate Cancer Treatment and Research(15), Immunotherapy and Immune Responses(12), Cancer, Lipids, and Metabolism(8)

Publications69 total

Considerations of non-human primate use in nonclinical toxicity study package for oncology therapeutics with well-characterized target in supports of 3Rs – an IQ DruSafe industry survey
Regulatory Toxicology and Pharmacology·2025· 1 cited
How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?
Regulatory Toxicology and Pharmacology·2025· 1 cited
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
Clinical Pharmacology & Therapeutics·2024· 2 cited
Data from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Supplementary Figure 1 from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Data from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Supplementary Methods, Figure Legend from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Figure 1 from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Supplementary Methods, Figure Legend from Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
2023Open Access
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Data from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Data from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Supplementary Figure S4 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Supplementary Figure S3 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Supplementary Figure S3 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Supplementary Methods and Tables from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
Supplementary Figure S5 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Peter Kufer(22), Tobias Raum(20), Matthias G. Friedrich(18), Patrick A. Baeuerle(15), Oliver S. Thomas(14), Roman Kischel(13), Petra Deegen(13), Angela Coxon(13), Julie M. Bailis(13), Matthias Friedrich(11), Patrick Hoffmann(10), Joachim Wahl(10), Pamela Bogner(10), Joachim Wahl(10), Katja Matthes(10), Anja Henn(9), Shyun Li(9), Famke Aeffner(9), Olivier Nolan-Stevaux(7), Michael Z. Liao(7)